Drug Trial Radar · NCT06784648
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Dec 11, 2024
Primary completion
Sep 9, 2026
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- BioInvent International ABIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jan 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically. Melanoma is a type of skin cancer that starts in melanocytes, the cells that make the pigment that gives skin its color. In people with cancer, the body cannot control the growth of cells, which can come together to form tumors. This trial's new treatment is called BI-1607. BI-1607 is designed to work by improving the effectiveness of other targeted therapies already used for melanoma treatment; ipilimumab and pembrolizumab. BI-1607 will improve the ability of these two treatments to help the body's defense system to destroy cancer cells.
Conditions
- Melanoma Metastatic
- Melanoma of Skin
- Melanoma BRAF V600E/K Mutated
- Melanoma Recurrent
- Melanoma Stage III or IV
- Melanoma
- Melanoma Negative for bRAF
- Melanoma Negative for nRAS
- Melanomas
- Uveal Melanoma, Metastatic
Interventions
pembrolizumab (KEYTRUDA®)Biological
fixed dose 200mg
BI-1607Biological
Each cohorts will receive either 350mg or 700mg per cycle for 4 cycles
Ipilimumab (YervoyTM, 50 mg/10 mL solution)Biological
Each cohort will receive either 1mg/kg or 3mg/kg for 4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
- Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
- Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
- Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
- Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
- Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
- Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
- Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
- Recommended doses for the expansion cohortTime frame: End of Cycle 3 (each cycle is 21 days)
- EfficacyTime frame: Through study completion, a maximum of 2 years
- EfficacyTime frame: Through study completion, a maximum of 2 years
- EfficacyTime frame: Through study completion, a maximum of 2 years
- EfficacyTime frame: Through study completion, a maximum of 2 years
- EfficacyTime frame: Through study completion, a maximum of 2 years
- EfficacyTime frame: Through study completion, a maximum of 2 years
- Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
University Hospital Heidelberg
Heidelberg, Germany
Hospital Universitario Vall d'Hebron
Barcelona, Spain
University Hospital 12 de Octubre
Madrid, Spain
Sarah Cannon Research Institute UK
London, Greater London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.